(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

## (19) World Intellectual Property Organization International Bureau





### (43) International Publication Date 17 July 2003 (17.07.2003)

**PCT** 

## (10) International Publication Number WO 03/057729 A3

- (51) International Patent Classification7: A61K 38/22, C12N 1/21, A01K 67/00
- C07K 14/575.
- PCT/EP03/00448 (21) International Application Number:
- (22) International Filing Date: 8 January 2003 (08.01.2003)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

02290030.2

8 January 2002 (08.01.2002)

- (71) Applicant (for all designated States except US): IN-STITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM [FR/FR]; 101, rue de Tolbiac, F-75013 PARIS (FR).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): GOFFIN, Vincent [BE/FR]; 2, impasse des Chèvrefeuilles, F-78910 ORGERUS (FR). BERNICHTEIN, Sophie [FR/FR]; 61, rue des Ecoles, F-93300 AUBERVILLIERS (FR). KELLY, Paul, A. [FR/FR]; 54, rue Notre Dame de Lorette, F-75009 PARIS (FR).

- (74) Agents: VIALLE-PRESLES, Marie José et al.; CAB-INET ORES, 36, rue de St-Pétersbourg, F-75008 PARIS (FR).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### Published:

- with international search report
- (88) Date of publication of the international search report: 16 October 2003

[Continued on next page]

(54) Title: MAMMAL PROLACTIN VARIANTS

hormones

&f Hormones	1	Helix 1
hPRL	LPICPGGAAR	COVTLRDLFDRAVVLSHYIHNLSSEMFS
hGH	F	PTIPLSRLFDNAMLRAHRLHQLAFDTYQ
hPRL mutants		
$\Delta$ 1-9-hPRL	<sup>10</sup> <b>R</b>	$\underline{\mathtt{SQVTLRDLFDRAVVLSHYIHNLSSEMFS}}$
$\Delta$ 1-10-hPRL	1	<sup>1</sup> SQVTLRDLFDRAVVLSHYIHNLSSEMFS
Δ1-11-hPRL		<sup>12</sup> QVTLRDLFDRAVVLSHYIHNLSSEMFS
$\Delta$ 1-12-hPRL		$^{13}$ VTLRDLFDRAVVLSHYIHNLSSEMFS
$\Delta$ 1-13-hPRL		14TLRDLFDRAVVLSHYIHNLSSEMFS
Δ1-14-hPRL		15LRDLFDRAVVLSHYIHNLSSEMFS

(57) Abstract: The invention relates to mammal prolactin (PRL) variants having a mutation or set of mutations within the 14 N-terminal amino acids thereby preventing the formation of a disulfide bridge between Cys4 and Cys11 and, a sterically hindering mutation or set of mutations within binding site 2 of PRL. These variants are useful as antagonists of mammal prolactin receptors (PRLR), more particularly of human prolactin receptor (hPRLR).





For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

# INTERNATIONAL SEARCH REPORT

Interpopular Application No PCT/EP 03/00448

A. CLASSI IPC 7	FICATION OF SUBJECT MATTER CO7K14/575 A61K38/22 C12N1/21	A01K67/00						
	International Patent Classification (IPC) or to both national classification	ation and IPC						
	SEARCHED  cumentation searched (classification system followed by dassification	on symbols)						
	Minimum documentation searched (classification system followed by classification symbols) IPC 7 CO7K A61K							
Documentat	ion searched other than minimum documentation to the extent that s	uch documents are included in the fields se	arched					
	Commission of the commission of the own that one found the same that of the same that of the same of t							
Electronic d	ata base consulted during the international search (name of data ba	se and, where practical, search terms used)						
EPO-Internal, BIOSIS								
C. DOCUM	ENTS CONSIDERED TO BE RELEVANT							
Category °	Citation of document, with indication, where appropriate, of the rela	evant passages	Relevant to claim No.					
γ	S. BERNICHTEIN ET AL.: "N-Termin Deletion in Human Prolactin Enhan Biological Activity and Reduces For Covalent Multimers" ENDO 2000, ENDOCRINE SOCIETY 82ND MEETING, TORONTO, June 2000 (2000-06), page 153 XF cited in the application abstract 613 page 153	oces formation O ANNUAL	1-12					
Further documents are listed in the continuation of box C.								
° Special car	legories of cited documents :	"T" later document published after the inter	national filing date					
	ent defining the general state of the art which is not	or priority date and not in conflict with t cited to understand the principle or the	the application but ory underlying the					
considered to be of particular relevance invention  "E" earlier document but published on or after the international "X" document of particular relevance; the claimed invention								
"L" docume	nt which may throw doubts on priority claim(s) or	cannot be considered novel or cannot involve an inventive step when the doc	zument is taken alone					
citation	which is cited to establish the publication date of enother  "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the							
other n		document is combined with one or moments, such combination being obviou in the art.	ne other such cocu— sto a person skilled					
	nt published prior to the international filling date but an the priority date claimed	*&* document member of the same patent f	amily					
I	actual completion of the international search	Date of mailing of the International sea	rch report					
3	June 2003	15/07/2003						
Name and malling address of the ISA Authorized officer European Patent Office, P.B. 5818 Patentlaan 2								
	NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,	01-1- D						
l	Fax: (+31-70) 340-3016	Stolz, B						

# INTERNATIONAL SEARCH REPORT

Intermonal Application No PCT/EP 03/00448

	<del></del>	PCT/EP 03/00448			
C-(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT					
Category °	Citation of document, with indication where appropriate, of the relevant passages	Relevant to claim No.			
Y	V. GOFFIN ET AL.: "Antagonistic Properties of Human Prolactin Analogs That Show Paradoxical Agonistic Activity in the Nb2 Bioassay" J. BIOL. CHEM., vol. 271, no. 28, 12 July 1996 (1996-07-12), pages 16573-16579, XP002921797 cited in the application Discussion	1-12			
<b>A</b> .	M. LLOVERA ET AL.: "Involvement of prolactin in breast cancer: redefining the molecular targets" EXPERIMENTAL GERONTOLOGY, vol. 35, 2000, pages 41-51, XP002198974 page 48, paragraph 2				
A	A. TCHELET ET AL.: "Selective Modification at the N-terminal Region of Human Growth Hormone That Shows Antagonistic Activity" MOLECULAR AND CELLULAR ENDOCRINOLOGY, vol. 130, 1997, pages 141-152, XP002198975 abstract				